We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Pharmacological Challenge Models in Clinical Drug Developmental Programs

*Salma Assil, Robert Rissmann and
Martijn Bastiaan Adriaan van Doorn*

Abstract

Early phase clinical research for drug development requires the investigation of safety, tolerability and efficacy of novel compounds. The latter is hampered by the absence of the disorder in healthy volunteers, which is why challenge models are often applied in order to demonstrate ‘proof of pharmacology.’ These challenge models can often be translatable from animal work and can inform the drug developer which dose, dosing regimen or application frequency should be selected prior to phase II studies in the target population. Furthermore, these challenge models represent well-controlled settings to perform activity screening of the compound. The following skin challenge models will be reviewed in this chapter: inflammation induced by Toll-like receptor agonists such as imiquimod, KLH challenge, UV-B irradiation and histamine.

Keywords: skin inflammation, immune system, imiquimod, translational model, pruritus, drug development

1. Introduction

Drug development programs are well-established and long-lasting processes, taking between 10 and 15 years, from discovery to market availability. Clinical trials with drug candidates are the final stage in drug development programs [1, 2]. These clinical trials are often classified into four stages of experimentation, phase I—IV, which are used as a general guideline in clinical trial research for development of a new treatment in specific diseases, i.e., skin diseases [3]. In general, safety, tolerability and pharmacokinetic properties are assessed in healthy volunteers during phase I. The candidate drug will move on to phase II when the initial safety and tolerability has been determined. The main aim of phase II is to establish the safety and efficacy of the drug in the target population. Phase III studies involve large-scaling testing to provide more and extended information on the effectiveness of the drug and on the benefits and possible adverse events. The last phase, IV, also known as the post marketing surveillance trials, is executed after the drug enters the market. The main purpose of this monitoring phase is to determine the long-term effectiveness and patient’s quality of life and cost-effectiveness [4, 5].

Translational research focuses on the transcription of the animal model into humans, also known as first-in-human-dose. In general, efficacy, safety and tolerability are examined in the early phases of clinical research. However, the absence

of the disorder in healthy volunteers may hamper investigation of the above-mentioned hallmarks of drug development. Inflammation, for example, plays an important role in diseases and is often an indication for a certain skin disease. Difficulties occur when testing drugs against inflammation in volunteers who do not have this condition. Therefore, pharmacological challenge models have been established to mimic physiological and pathophysiological conditions of several skin diseases. These models distort the physiological condition and lead to temporary effects that mimic the pathophysiology of the disease.

Table 1 gives an overview of established skin challenge models.

This approach includes translating basic scientific discoveries into clinical applications. Several recent developments in plaque psoriasis are noteworthy, which serve as an example of research with many translational aspects [42, 43]. Psoriasis is a chronic, inflammatory skin disease that is characterized by erythematous, itchy plaques covered by course scales on the extensor surface of the elbows and knees, as well as the scalp, dorsal hands and lumbar area. Also, the nails and joints (psoriatic arthritis) can be affected [44, 45]. Psoriasis is a multifactorial disease but the

Challenge	Application	Mode of action	Condition induced	Immune response	Reference
<i>Inflammation</i>					
BCG	Intradermal	TLR 4, 9 agonist	Local inflammation, systemic immune response	Adaptive	[6–8]
Imiquimod	Local under occlusion	TLR7 agonist	Local inflammation	Innate + adaptive	[9–13]
LPS challenge + Al(OH) ₃	Intra dermal	TLR 4 agonist	Inflammatory response	Innate + adaptive	[14, 15]
Cantharidin	Paper disc with cantharidin	Neutrophils	Local inflammation	Innate	[14, 16]
Injected UV killed E. coli	Intradermal	Neutrophils	Erythema, heat, swelling and pain	Innate	[14, 17]
KLH	Intradermal, Intramuscular	Neo-antigen	Local inflammation, systemic immune response	Adaptive	[18–22]
<i>ITCH</i>					
Capsaicin	Intradermal, intra muscular, topical	TRPV 1 receptor	Itch	Innate	[23–25]
Histamine	Intradermal, intramuscular	H1, 2, 3, 4 receptor C _{MIA} fibers	Itch	Innate	[26–33]
Cowhage	Cutaneous	CMH-fibers	Itch Burning	Unknown	[34, 35]
<i>UV-exposure</i>					
UV-B irradiation	Local thermode	PI3K/AKT/ mTOR-upregulation	Pain, pigmentation, erythema, inflammation	Innate Adaptive	[23, 36–41]
BCG: <i>Bacillus Calmette-Guérin</i> ; LPS challenge: <i>lipopolysaccharide</i> ; injected UV killed E. coli: <i>Injected ultraviolet killed Escherichia coli</i> ; KLH: <i>keyhole limpet hemocyanin</i> ; UV-B: <i>Ultraviolet B</i> .					

Table 1.
Overview of human skin challenge models.

hallmarks of pathophysiological pathways (Th1/Th17) with interleukin-12/23 and IL-17 have been clearly established as most important players. Over the last decade many new compounds have been in development for psoriasis yielding a total of 11 registered, targeted monoclonal antibodies today. In these drug development programs *in vivo* models in mice are of great importance for the setup of clinical programs. These mouse models needed to be made suitable to display certain features of psoriasis, since mice are unable to develop psoriasis themselves [10]. This research resulted in development of diverse mouse models i.e., spontaneous mutation model, genetically engineered model, cytokine injection model and transplantation model. All of the mentioned animal approaches represent more or less psoriasis-like cutaneous characteristics. Despite expression of psoriasis like features, the models also have some limitations including the need for special experimental facilities and lack of effectiveness of anti-psoriatic drugs [46–49]. In general, animal models are far from perfect especially in terms of pharmac- and toxicokinetics.

Animals are not able to predict health effects in humans better than humans themselves. Monkeys reflects the human being the best, however, even they can differ as became clear in 2016. An anti-CD28 antibody caused multiple organ failures in six healthy volunteers within hours, despite multiple normal tests in monkeys. This shows that animal models may have limited predictability for safety in humans. Ethical concerns with regard to need for animal testing may also be a factor underlining the need for pharmacological challenge models in humans [50].

This chapter will provide a detailed overview of four different, local inflammation models: inflammation by Toll-like receptor agonists such as imiquimod (inflammation), UV-B irradiation (inflammation and pain), histamine provocation (itch) and KLH challenge (delayed type hypersensitivity).

2. Imiquimod skin inflammation model

Skin inflammation is a common response of our immune system to penetrating pathogens, skin trauma, exposure of xenobiotics, microbes and parasites [51–53]. Inflammation is clinically recognizable by erythema, pain, heat and swelling [54]. Generally, in inflamed skin, various immune cells, of both the innate and adaptive system are involved to combat the pathogens. However, imbalance of these immune cells may lead to chronic skin diseases such as psoriasis vulgaris, atopic dermatitis and acne vulgaris. Currently, many investigations are addressing the biomolecular mechanisms of inflammation; however, the pathophysiology of the skin remains complex and needs further investigation [55, 56].

Hence, various models in healthy volunteers were developed that mimic inflamed skin conditions [57]. One of the examples is the challenge model with topical application of imiquimod, the active ingredient of Aldara cream. Imiquimod is a small molecule with a low molecular weight and high lipophilicity which is preferable for absorption in the skin after topical administration. This small molecule is also a ligand for toll-like receptor seven and eight (TLR), which belongs to the class of immunomodulatory agents and is able to induce the production of several cytokines (interferon-1 response) with antiviral and tumoricidal properties. The mechanism of action of imiquimod is complex and three main pathways are required including TLR signaling, inflammasome activation and inhibition of the adenosine receptor. However, limited information is available on the mechanism of imiquimod on the adenosine receptor. The first pathway is TLR dependent and activates nuclear factor kappa B (NF- κ B) signaling *via* MyD88, which is important in an early immune response. Herewith, activation of c-Jun and IRAK pathways occur which are involved in the production of several

pro-inflammatory cytokines. The second pathway is TLR independent. Imiquimod is able to activate the inflammasome *via* the NALP3 pathway, which also triggers an immune response and leads to production of interleukin-1 β (IL-1 β , a pro-inflammatory cytokine) [10, 11, 13, 58–60].

Aldara 5% cream is registered as a topical product that is indicated for the treatment of superficial basal cell carcinoma, actinic keratosis and genital and peri-anal warts (condyloma acuminata). Topical administration of imiquimod appears to be safe and reasonably tolerated according to the mouse model. This murine imiquimod challenge model has been widely used to examine the mechanisms involved in psoriasis vulgaris, since it is simple, inexpensive and develops an acute inflammatory response with psoriasiform features. However, in general, the main limitation of murine models is that no single mouse model is able to reflect human disease precisely, as the physiology and the pathophysiology of the skin differs in both species [61]. Therefore, recently, human studies been conducted that study skin inflammation after topical application of imiquimod.

Vinter et al. successfully developed an imiquimod-induced psoriasis-like skin inflammation model in humans by applying imiquimod topically under occlusion on non-lesional psoriatic skin of the lower back. A group of patients (n = 7) received the treatment and vehicle for 2 days, while the other group (n = 3) received the same treatment for 7 days. All the treatments were applied on tape stripped skin resulting in perturbation of the skin barrier. After 2 days of treatment with imiquimod, a significant upregulation in mRNA expression was observed for the pro-inflammatory cytokines tumor necrosis factor α (TNF- α), IL-1 β and IL-6, whereas TNF- α and IL-6 are keratinocyte driven cytokines. Additionally, a high level of IFN- γ and IL-10 was found, the latter has an important role in suppression of the inflammatory response in the skin, as it influences the regulatory T-cells. In this model, inflammation and psoriasis-like characteristics were induced; however, typical psoriasis lesions were not observed and therefore appear to be the main limitation of the study.

A different approach to study skin inflammation was established by Van der Kolk et al. by applying imiquimod topically to healthy volunteers under occlusion. A distinction between the two groups was made. The first cohort received a topical treatment for 24, 48 and 72 hours on the intact skin barrier, while the second cohort received exactly the same treatment on a compromised skin barrier, through tape stripping (**Figure 1**). In this open label, dose-ranging study, erythema and blood perfusion were monitored by means of erythema index photo analysis, erythema colorimetry, erythema visual grading and laser speckle contrast imaging (LSCI). A dose-dependent increase in erythema was observed for all measurements, with a more rapid and pronounced effect in the tape stripped group. This model showed no clear differences in erythema intensity between the treatments after 48 and 72 hours, which is in concordance with observations in the murine model [9, 13]. Additionally, an increased skin perfusion was found after treatment with imiquimod, however this was only observed in the tape stripped cohort. A similar effect was found for the biomarkers in skin biopsies. Tape-stripping combined with imiquimod treatment resulted in an upregulation of gene expression of CXCL10, MX-A, ICAM-1 and hBD-2 after 48 and 72 hours. The same results were observed after treatment with imiquimod only compared to vehicle, however to a lesser extent. Imiquimod has a three-step mechanism, which entails an initial (24 hour), intermediate (24–72 hour) and late phase (>72 hour). In the intermediate phase of imiquimod, activation of both the innate and adaptive immune response takes place, which is characterized by infiltration of neutrophils, lymphocytes, and macrophages, based on the findings reported in the review of translational imiquimod skin inflammation

Figure 1.
Overview of the treatment schedule. (a) Treatment areas 1, 2 and 3 were treated with 5 mg imiquimod respectively for 24, 48 and 72 hours. All treatments were applied under occlusion by a 12 mm Finn chamber. (b) Clinical impression of site 3 of the tape stripped cohort after 72 hours of imiquimod treatment [9]. Permitted for non-profit use.

models [59]. In addition, histologically, infiltration of CD11+, HLA-DR, CD4+ and CD8+ into the dermis was observed. Increased infiltration was more pronounced in the tape stripped cohort, however, no differences were observed between 48 and 72 hours of treatment [9].

This chapter focuses mainly on translating skin inflammation into a model that can be used in healthy human volunteers. In the past decades, a lot of research has been performed in this field; however, murine models remained the gold standard. Since skin inflammation plays a crucial role in skin diseases such as psoriasis and atopic dermatitis, Vinter et al. established a human counterpart to the mouse model of imiquimod-induced psoriasis like skin inflammation [13]. Despite the expression of different pro-inflammatory cytokines and the presence of psoriasis-like features, typical psoriasis lesions were not observed. However, this study formed the base to the inflammation model developed by Van der Kolk et al. where imiquimod has been applied under occlusion to challenge the skin. This model resulted in expression of certain cytokines and chemokines that are involved in activation of innate as well as adaptive immune system. Chemokines such as CXCL10 are expressed through activation of keratinocytes in inflamed skin. Expression of MX-A, a downstream interferon, which corresponds with the activation of plasmacytoid dendritic cells (pDCs), was also upregulated in the tape stripped cohort. The presence of interferons reflects the antiviral response, which is in concordance with the antiviral characteristics of imiquimod, used for HPV-induced diseases [62, 63]. Based on these findings, the murine imiquimod skin inflammation model was translated to a safe, human model in healthy volunteers. Skin erythema, skin perfusion and expression of cytokines had high intensity in the tape stripped cohort due to the enhanced transepidermal drug delivery. This model is suitable as a challenge model and can be used in drug developmental programs where TLR 7 is involved. Currently, several drugs are under development targeting TLR7/8 that have anti-tumor characteristics with more than 30 leads to be explored within the next years [64, 65].

3. Models for itch: histamine and cowhage provocation

Itch, interchangeably used as pruritus, is a common skin sensation and together with pain are crucial symptoms in many chronic and allergic skin diseases. Itch can be induced by mechanical, thermal and chemical stimuli. Additionally, itch can lead to impairment of the skin and thereby affect a person's quality of life. Yosipovitch et al. defined different types of pruritus that are involved in chronic itch including pruriceptive, neuropathic, neurogenic and psychogenic itch. Skin inflammation, dryness, or other skin damage are the main factors causing pruriceptive itch and are found in diseases such as scabies, urticaria and insect bite reactions [66, 67]. Neuropathic itch, is usually caused by nerve injury and can arise at any point along the afferent pathway of the neurons. This itch is observed for example after a varicella zoster infection or nerve trauma. Itch that is originated from activation of the central nervous system is called neurogenic itch. The underlying mechanism is complex since it involves pruriceptive itch as well. This itch is often observed in visceral disease states such as end state renal disease or kidney failure. The last subtype of itch is termed psychogenic itch. This type of itch arises with somatization and the delusional state of parasitophobia [66–68]. In this chapter, we will focus on pruriceptive itch and the translational model for it.

Generally, theories have been proposed that explained the relation between itch and pain. Itch is mediated through weak activation of nociceptors and stronger activation would result in weak pain. This is also called, the intensity theory. However, further research has elucidated new aspects that explain pruriceptive sensory mechanism in the nervous system. This resulted in two main pathways including specificity and pattern theories. The specificity theory, explains that there are different sets of neuron fibers transferring information to the central nervous system which send responsive signals including itch and pain [25, 35]. The pattern theory stipulates that many sensory receptors and spinal cord neurons are involved in sensation of itch [69]. Although, the neural mechanism of pruritus has been investigated extensively, there remains much to be learned. Therefore, studies that use chemical agents to induce itch have been designed to study the sensory patterns of itch and pain in humans.

One of the most frequently and widely used pruritic agent, that evokes itch, is histamine [70]. Originally, histamine is a neurotransmitter that is associated with pathological processes such as inflammation, pruritus and vascular leak. Histamine is stored in several immune cells, basophils and mast cells and is quickly released after stimulation. Stimulation with histamine, triggers the unmyelinated nerve fibers, also known as C-fibers. A subset of C-fibers (CMi or CMh) is stimulated according the intensity of the stimulus. In case of histamine stimulation, sustained response of CMi occurs [71]. Histidine decarboxylase (HDC), an enzyme that is responsible for histamine production, increases through stimulation with certain mediators that are found in skin lesions of patients with atopic dermatitis. Hence, this enhancement is associated with upregulated histamine release and thus with increased itch sensitivity [28, 70].

Histamine has been used in literature as an important inflammatory mediator that is responsible for vascular and inflammatory effects [33]. In the early 1900s the first studies were conducted regarding the potential vascular role of histamine *in vivo*, however, only a couple of years ago a clinical study was conducted that investigated the cutaneous inflammatory response in human skin. Falcone et al. has developed an easy-to-use model to study the early stages of skin inflammation. Eighteen (18) subjects with Fitzpatrick skin type II and III received topically applied histamine after performing histamine iontophoresis. The subject had to

rate their perceived itch on visual analog scale (VAS) with 3 being the threshold for willingness to scratch the skin. Additionally, different skin assessments were performed including trans-epidermal water loss, skin redness and punch biopsy to process immunohistochemistry. Itch was observed up to 30 minutes after stimulation with histamine iontophoresis and was above the itch threshold (VAS > 3). Immunohistochemistry showed an increase of the epidermal thickness, after 72 hours of histamine iontophoresis challenge. In summary, this model can be used as an *in vivo* model to provoke local and acute skin inflammation, without having an impact on the barrier function. However, no data are available on cell level or cytokine expression profiles [29].

As was earlier described, increased production of histamine has been related to several skin diseases including atopic dermatitis. In addition, histamine has been the main prototypical pruritogen that has been used for experimental purposes. The working mechanism of histamine is going *via* G- protein coupled receptors: H1 up and till H4. It appears that the H1 and H4 receptors play a role in the histamine involved itch response in mice. In humans, the involvement of other receptor subtypes (H2 and H3) in itch is not well-examined in literature [31, 32]. Generally, the classical anti-histamines bind to H1 receptor and are prescribed in patients suffering from atopic dermatitis. However, recent research clarifies that histamine pathway is not playing a major role in atopic dermatitis. Also, the clinical use of anti-histamines in atopic dermatitis population has been ineffective and questionable which corroborates these findings [27, 32, 72].

Therefore, there was a need to establish an alternative itch model, relating to another pathway. The pruritus pathway has physiological functions such as skin barrier homeostasis, inflammation, itch and pain and is the protease-activated receptor (PAR) pathway. PARs are classified as G-protein-coupled receptors and consist of four members, PAR-1, PAR-2, PAR-3 and PAR-4, whereas PAR-2 pathway is mainly associated with skin diseases such as atopic dermatitis [26]. Papoiu et al. established a simple human model based on exogenously stimulation of the PAR-2 pathway in order to provoke itch by applying Cowhage spicules. Additionally, the Cowhage model was compared to the traditional histamine iontophoresis model and the effect of the combined model (histamine iontophoresis and Cowhage) was observed. VAS rating was increased in both atopic dermatitis patients and healthy volunteers, the Cowhage and combination model compared to the histamine model, resulting in no synergy between the Cowhage and the combined model. This finding suggests that Cowhage was the major contributor of itch after stimulation of both pathways simultaneously [34]. The Cowhage model is simple and easy to use and could serve to study itch related skin diseases such as atopic dermatitis. On the other hand, less is known about this pathway and more research is required to examine the mechanism behind this model.

In conclusion, two main skin challenge models were described to provoke itch: histamine iontophoresis and Cowhage. Both models are suitable to use, however, both have a different underlying mechanism to elicit the itch sensation. Evidence-based, induction of the PAR-2 pathway plays a major role in atopic dermatitis, causing pruritus, compared to the histamine model. Therefore, from a therapeutic point of view, drugs that inhibit PAR-2 itch pathway, could be promising, leading to development of a new treatment for chronic pruritus. Since less is known about the underlying cellular mechanism of Cowhage, it would be useful to examine biomarker expression, conduct different skin photography assessments and look at the skin vascularity flow. Furthermore, an advanced challenge study is required in healthy volunteers and patients with atopic dermatitis to examine and monitor the inflammation of both models. In addition, the efficacy of anti-histamine agents and PAR-2 antagonists could be evaluated as well.

4. Model for inflammation and pain: UV-B skin irradiation

Ultraviolet (UV) radiation is classified as a carcinogenic compound since it has the ability to initiate and promote malignant skin tumors. Additionally, increased exposure to UV radiation can lead to other skin problems such as inflammation and degenerative aging. UV energy is subdivided into three main classes based on physical properties: UV-A, UV-B and UV-C. UV-B can cause physiological skin alterations leading to a cascade of cytokine activation and resulting in an inflammatory response, so called “sunburn”. Furthermore, exposure to UV-B is related to the accumulation of epidermal keratinocytes and thereby increases the epidermal thickness. UV-B radiation has an additional effect on the skin, it is able to up-regulate the production and the accumulation of melanin in the skin and is also linked to cancer susceptibility.

In well-controlled clinical settings, exposure to UV-B is widely used as a human and animal challenge model to induce local cutaneous hyperalgesia (pain) and inflammation. Primary hyperalgesia is induced after 24 hours and remains for more than 48 hours which makes the model suitable for studies where multiple dosing is required. The amount of UV-B radiation applied to the skin needs to be adjusted to a subject’s skin type, according the classification of Fitzpatrick Skin Type [73, 74]. Hereafter, prior the start of the challenge, the Minimal Erythema Dose (MED) is determined and subsequently a one-, two- or threefold multiple of this dose is applied to the skin. After 24 hours, skin inflammation occurs.

This UV model is one of the pain models that can be used as a screening tool for early stage clinical drug development. However, in research, the UV model is used to examine the effects of anti-analgesic or local anesthetics [75, 76]. Recently, an article was published where the UV-B model was one of the models that was applied to compare the effects of several analgesic to placebo. The following analgesic compounds were investigated in the first part: fentanyl, phenytoin, (S)-ketamine and placebo. For the second part of the study imipramine, pregabalin, ibuprofen and placebo were examined. Different pharmacodynamic (PD) assessments were performed which are part of the pain cart including thermal grill, thermode testing and UV-B, electrical stimulation test, pressure stimulation and cold pressure test [41]. Whilst, this study was performed to examine systemic effects of analgesic compounds, the topical effect of UV-B radiation was not determined. One article published the effects of single doses of UV-A, UV-B and UV-C on skin blood flow and barrier function by laser-Doppler flowmeter and evaporimetry. Radiation with various UV light resulted in skin inflammation characterized by erythema, however, assessed visually. Visual perception of erythema correlated with the increase in blood flow assessed by laser-Doppler flowmeter. However, UV radiation has not damaged the skin barrier function, since the trans- epidermal water loss was not increased. An exception formed the three MED, an increase in blood flow was observed after 2 weeks [38]. This study has examined the effects of analgesics on UV-B radiation and other models evoking pain, while skin inflammation occurs as well. Only a few *in vivo* studies attempted to examine the effect of UV-B radiation on skin inflammation. In general, UV-B radiation triggers the production of inflammatory cytokines in the human keratinocyte cell line HaCaT, including IL-1, IL-6, IL-8, IL-10 and TNF- α , which are leading to alterations of immune cells of the skin [39]. However, involvement of immune cells in skin inflammation after UV-B radiation has not yet been examined and monitored in healthy volunteers.

For future perspectives, the UV-B challenge model could be applied to induce temporarily skin inflammation that could be monitored with additional dermatological tests, such as multispectral imaging, thermography and laser speckle contrast imaging.

5. KLH challenge

Challenge models that are described in this chapter, were mostly initiating an innate response, except the imiquimod challenge model. However, in auto-immune skin diseases, activation of the adaptive immune system is crucial as well as the involvement of T-cells [77]. It is quite challenging to evaluate the efficacy of novel drugs in healthy volunteers that target T-lymphocytes, since these are in the resting phase. Hence, challenge models could provide the desirable solution by activating autoreactive T-cell pathways in healthy volunteers. Earlier research investigated keyhole limpet hemocyanin (KLH) as a potential immunization candidate for studying the cell-mediated immune response [78]. KLH is a large molecule (~8000 kDa) consisting of several subtypes and has been widely used in animal and human research for more than 40 years to outline cellular and humoral responses [79–81]. Additionally, KLH can be used as a carrier protein for cancer vaccines and for bladder cancer immunotherapy [20, 82]. Because of the xenogeneic properties to the human immune system, KLH is able to promote a reliable primary immune response. The following administration routes are known and have been used in earlier research—intradermal, subcutaneous, intramuscular and inhalational [21, 22, 83–87]. Furthermore, KLH is considered to be clinically safe, since no reports are available on significant adverse events as reported in the comprehensive review by Harris & Markl. Only mild adverse events were reported including itch, rash and mild injection site reactions (soreness) [19, 88]. In summary, single dose immunization with KLH evokes a predictable primary T-cell dependent immune response. An additional intradermal dose of KLH will result in an additional immune response and thereby induces a delayed type IV hypersensitivity reaction around the site of injection [78].

Presence of erythema and induration are features of a cell-mediated immune response and are generally scored by visual inspection, which is a subjective method and may lead to significant interrater variability. Saghari et al. established a challenge model to activate T-cells in healthy volunteers after immunization with KLH, whereas both the cellular response and the delayed type hypersensitivity are objectively quantified. Adaptive immunity was measured by anti-KLH IgM and IgG blood serum level titers. Additionally, cutaneous blood perfusion, erythema and swelling were objectively measured by respectively laser speckle contrast imaging (LSCI), multispectral imaging and colorimetry. An increase in anti-KLH IgM and IgG was observed after intramuscular KLH administration compared to placebo. This was the case for the cutaneous blood perfusion quantified by LSCI and for the erythema and swelling quantified by multispectral imaging and colorimetry. So far, none of the studies have quantified induration and erythema response by using non-invasive instruments. This model is developed as proof-of-concept to determine the feasibility and to quantify the features of cell-mediated response [89]. Therefore, the delayed type hypersensitivity model can serve as a candidate to study the pharmacological and pharmacodynamic effects of immunomodulators in healthy volunteers.

6. Conclusion

Generally, *in vivo* mice models are a crucial part in pre-clinical drug developmental programs, assessing safety. However, often animal models lack the disease or differ in morphological and physiological properties. Ethical concerns with regard to animal studies are an additional issue which prompts to search for new solutions. Currently, safety is assessed in healthy volunteers who hamper the disease.

Therefore, challenge models that mimic the disease temporarily, could provide a possible solution and act as translational models. This chapter has provided an overview (**Table 1**) of various challenge models that are known to initiate skin inflammation by triggering the human immune system. First, the human imiquimod challenge model was introduced as a safe and well-tolerated model to study temporarily induced skin inflammation by targeting the TLR7/8 receptor. The effect on erythema, cutaneous perfusion and biomarker expression was more pronounced in the group with the perturbed skin barrier due tape stripping. Nowadays, this imiquimod model can be applied to test agents that target TLR7/8 receptor with anti-tumor characteristics.

Furthermore, two models for pruritus were described focusing on two different mechanisms. The first model used histamine as pruritogen to evoke itch *via* a subset of C-fibers. An upregulation of HDC is associated with an increase in histamine release and is found in the lesions of patients suffering from atopic dermatitis. Anti-histamines are often prescribed against itch in patients with atopic dermatitis even though they are ineffective. Therefore, an alternative model was developed targeting the PAR-2 pathway. In this model, itch was initiated by applying Cowhage spicules to the forearm of healthy volunteers and patients with atopic dermatitis. The itch sensation was based on VAS score and EASI (in patients with atopic dermatitis), both giving qualitative measures.

Another model that has been described in this chapter is the UV-B radiation model, which is used to induce pain stimulus in healthy volunteers. A couple of studies elucidates the occurrence of skin inflammation after UV-B radiation. However, no research has been done that focuses on skin inflammation in humans after using UV-B radiation.

The last model of this chapter triggering neo-antigen, is the KLH challenge model in healthy volunteers. KLH caused a delayed type IV immune response. An increase in cutaneous blood perfusion, erythema and swelling was observed after administration of KLH. This model could be used for proof-of-concept studies.

In general, all the challenge models that have been developed could be optimized by assessing pharmacodynamic endpoints focusing on the four pillars imaging, biophysical, clinical and cellular/molecular that together constitute a so-called 'dermatological toolbox'. For imaging, various tools can be used such as multispectral imaging, 2D/3D imaging, colorimetry and optical coherence tomography. Laser speckle contrast imaging, trans-epidermal water loss, thermography, transdermal analysis patch and microbiome analyses are able to provide objective information on biophysical condition of the skin. For completeness of the derma toolbox it is recommended to include the NRS pain/itch or VAS as well as the skin histology, immunohistochemistry and mRNA expression. This toolbox will allow us to develop and monitor advanced human skin challenge models that will provide a more holistic view and to move a step closer towards 'systems dermatology'.

Conflict of interest

No conflicts of interest.

IntechOpen

Author details

Salma Assil¹, Robert Rissmann¹ and Martijn Bastiaan Adriaan van Doorn^{2*}

1 Centre for Human Drug Research, Leiden, The Netherlands

2 Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands

*Address all correspondence to: m.b.a.vandoorn@erasmusmc.nl

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Pocock SJ. Clinical Trials: A Practical Approach. Chichester: Wiley & Sons; 2013. pp. 1-263
- [2] Rubio DM, Schoenbaum EE, Lee LS, Schteingart DE, Marantz PR, Anderson KE, et al. Defining translational research: Implications for training. *Academic Medicine*. 2010;**85**(3):470-475
- [3] Sedgwick P. What are the four phases of clinical research trials? *British Medical Journal*. 2014;**348**:1-2
- [4] Trials AC. Phases of clinical trials Australian Clinical Trials. 2015 Available from: <https://www.australianclinicaltrials.gov.au/what-clinical-trial/phases-clinical-trials>
- [5] Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: A narrative review. *Postgraduate Medicine*. 2011;**123**(5):194-204
- [6] Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, et al. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. *The Journal of Infectious Diseases*. 2014;**209**(8):1259-1268
- [7] McShane H, Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. *Tuberculosis*. 2014;**94**(2):105-110
- [8] Talat Iqbal N, Hussain R. Non-specific immunity of BCG vaccine: A perspective of BCG immunotherapy. *Trials in Vaccinology*. 2014;**3**:143-149
- [9] van der Kolk T, Assil S, Rijneveld R, Klaassen ES, Feiss G, Florencia E, et al. Comprehensive, multimodal characterization of an imiquimod-induced human skin inflammation model for drug development. *Clinical and Translational Science*. 2018;**11**(6):607-615
- [10] Vinter H, Iversen L, Steiniche T, Kragballe K, Johansen C. Aldara®-induced skin inflammation: Studies of patients with psoriasis. *The British Journal of Dermatology*. 2015;**172**(2):345-353
- [11] Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. *Nature Immunology*. 2002;**3**(2):196-200
- [12] Schon MP, Schon M. Imiquimod: Mode of action. *British Journal of Dermatology*. 2007;**157**:8-13
- [13] van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. *Journal of Immunology*. 2009;**182**(9):5836-5845
- [14] Maini AA, George MJ, Motwani MP, Day RM, Gilroy DW, O'Brien AJA. Comparison of human neutrophils acquired from four experimental models of inflammation. *PLoS ONE*. 2016;**11**(10):e0165502
- [15] Monnet E, Lapeyre G, Poelgeest EV, Jacqmin P, Graaf K, Reijers J, et al. Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. *Clinical Pharmacology and Therapeutics*. 2017;**101**(2):200-208
- [16] Dinh PH, Corraza F, Mestdagh K, Kassenger Z, Doyen V, Michel O. Validation of the cantharidin-induced skin blister as an in vivo model of inflammation. *British*

Journal of Clinical Pharmacology.
 2011;**72**(6):912-920

[17] Motwani MP, Flint JD, De Maeyer RP, Fullerton JN, Smith AM, Marks DJ, et al. Novel translational model of resolving inflammation triggered by UV-killed *E. coli*. The Journal of Pathology. Clinical Research. 2016;**2**(3):154-165

[18] Dickson MC, Dewit OE, Peters G, Norton N, McHugh S, Davis B, et al. Immunisation challenges with keyhole limpet haemocyanin (KLH) and bacteriophage PhiX174: Potential for modelling in vivo pharmacodynamic effects. Immunology. 2014;**143**:70

[19] Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): A biomedical review. Micron. 1999;**30**(6):597-623

[20] Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: A long-term follow-up study. European Urology. 2000;**37** (Suppl 3):45-49

[21] Miller JS, Curtsinger J, Berthold M, Malvey K, Bliss RL, Le CT, et al. Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clinical Immunology. 2005;**117**(2):144-151

[22] Spazierer D, Skvara H, Dawid M, Fallahi N, Gruber K, Rose K, et al. T helper 2 biased de novo immune response to keyhole limpet hemocyanin in humans. Clinical and Experimental Allergy. 2009;**39**(7):999-1008

[23] Bishop T, Ballard A, Holmes H, Young AR, McMahon SB. Ultraviolet-B induced inflammation of human skin: Characterisation and comparison with traditional models of hyperalgesia. European Journal of Pain. 2009;**13**(5):524-532

[24] Holst H, Arendt-Nielsen L, Mosbech H, Serup J, Elberling J. Capsaicin-induced neurogenic inflammation in the skin in patients with symptoms induced by odorous chemicals. Skin Research and Technology. 2011;**17**(1):82-90

[25] McMahon SB, Koltzenburg M. Itching for an explanation. Trends in Neurosciences. 1992;**15**(12):497-501

[26] Akiyama T, Lerner EA, Carstens E. Protease-activated receptors and itch. Handbook of Experimental Pharmacology. 2015;**226**:219-235

[27] Criado PR, Criado RF, Maruta CW, Machado Filho C. Histamine, histamine receptors and antihistamines: New concepts. Anais Brasileiros de Dermatologia. 2010;**85**(2):195-210

[28] De Benedetto A, Yoshida T, Fridy S, Park JES, Kuo IH, Beck LA. Histamine and skin barrier: Are histamine antagonists useful for the prevention or treatment of atopic dermatitis? Journal of Clinical Medicine Research. 2015;**4**(4):741-755

[29] Falcone D, Uzunbajakava N, Richters R, van de Kerkhof PCM, van Erp PEJ. Histamine iontophoresis as in vivo model to study human skin inflammation with minimal barrier impairment: Pilot study results of application of the model to a sensitive skin panel. Skin Pharmacology and Physiology. 2017;**30**(5):246-259

[30] Gutowska-Owsiak D, Greenwald L, Watson C, Selvakumar TA, Wang X, Ogg GS. The histamine-synthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin. British Journal of Dermatology. 2014;**171**(4):771-778

[31] Hanifin JM. The role of antihistamines in atopic-dermatitis. Journal of Allergy and Clinical Immunology. 1990;**86**(4):666-669

- [32] Rossbach K, Nassenstein C, Gschwandtner M, Schnell D, Sander K, Seifert R, et al. Histamine H1, H3 and H4 receptors are involved in pruritus. *Neuroscience*. 2011;**190**:89-102
- [33] Sandilands EA, Crowe J, Cuthbert H, Jenkins PJ, Johnston NR, Eddleston M, et al. Histamine-induced vasodilatation in the human forearm vasculature. *British Journal of Clinical Pharmacology*. 2013;**76**(5):699-707
- [34] Papoiu ADP, Tey HL, Coghill RC, Wang H, Yosipovitch G. Cowhage-induced itch as an experimental model for pruritus. A comparative study with histamine-induced itch. *PLoS ONE*. 2011;**6**(3):1-5
- [35] Schmelz M. Itch and pain. *Neuroscience and Biobehavioral Reviews*. 2010;**34**(2):171-176
- [36] Assarsson M, Duvetorp A, Dienus O, Soderman J, Seifert O. Significant changes in the skin microbiome in patients with chronic plaque psoriasis after treatment with narrowband ultraviolet B. *Acta Dermato-Venereologica*. 2018;**98**(4):428-436
- [37] Elwood JM, Diffey BL. A consideration of ambient solar ultraviolet-radiation in the interpretation of studies of the etiology of melanoma. *Melanoma Research*. 1993;**3**(2):113-122
- [38] Frodin T, Molin L, Skogh M. Effects of single doses of UVA, UVB, and UVC on skin blood-flow, water-content, and barrier function measured by laser-doppler flowmetry, optothermal infrared spectrometry, and evaporimetry. *Photodermatology*. 1988;**5**(4):187-195
- [39] Kim Y, Lee SK, Bae S, Kim H, Park Y, Chu NK, et al. The anti-inflammatory effect of alloferon on UVB-induced skin inflammation through the down-regulation of pro-inflammatory cytokines. *Immunology Letters*. 2013;**149**(1-2):110-118
- [40] Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. *Toxicology and Applied Pharmacology*. 2004;**195**(3):298-308
- [41] Okkerse P, van Amerongen G, de Kam ML, Stevens J, Butt RP, Gurrell R, et al. The use of a battery of pain models to detect analgesic properties of compounds: A two-part four-way crossover study. *British Journal of Clinical Pharmacology*. 2017;**83**(5):976-990
- [42] Drolet BC, Lorenzi NM. Translational research: Understanding the continuum from bench to bedside. *Translational Research*. 2011;**157**(1):1-5
- [43] Guttman-Yassky E, Krueger JG. Psoriasis: Evolution of pathogenic concepts and new therapies through phases of translational research. *The British Journal of Dermatology*. 2007;**157**(6):1103-1115
- [44] Krueger JG, Bowcock A. Psoriasis pathophysiology: Current concepts of pathogenesis. *Annals of the Rheumatic Diseases*. 2005;**64**:30-36
- [45] Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. *Journal of Clinical Investigation*. 2004;**113**(12):1664-1675
- [46] Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: What we have learned from mouse models. *Nature Reviews Rheumatology*. 2010;**6**(12):704-714
- [47] Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. *Journal of Investigative Dermatology*. 2007;**127**(6):1292-1308

- [48] Schon MP. Animal models of psoriasis: A critical appraisal. *Experimental Dermatology*. 2008;**17**(8):703-712
- [49] Suckling K. Animal research: Too much faith in models clouds judgement. *Nature*. 2008;**455**(7212):460
- [50] Hartung T. Thoughts on limitations of animal models. *Parkinsonism & Related Disorders*. 2008;**14**(Suppl 2):S81-S83
- [51] Schon MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4⁺ T cells. *Nature Medicine*. 1997;**3**(2):183-188
- [52] Leung DYM, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. *Journal of the American Academy of Dermatology*. 2001;**44**(1):S1-S12
- [53] Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. *Immunology Today*. 1998;**19**(1):37-44
- [54] Tracy RP. The five cardinal signs of inflammation: Calor, dolor, rubor, tumor... and penuria (apologies to Aulus Cornelius Celsus, De medicina, c. AD 25). *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*. 2006;**61**(10):1051-1052
- [55] Bieber T. Mechanisms of disease: Atopic dermatitis. *New England Journal of Medicine*. 2008;**358**(14):1483-1494
- [56] Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. *Nature Reviews. Immunology*. 2014;**14**(5):289-301
- [57] Dickson MC, Ludbrook Valerie J, Perry Hayley C, Wilson Paul A, Garthside Sam J, Binks MH. A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: A potential translational model for drug development. *Inflammation Research*. 2015;**64**(3-4):171-183
- [58] Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. *Journal of the American Academy of Dermatology*. 2004;**51**(4):547-555
- [59] Flutter B, Nestle FO. TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. *European Journal of Immunology*. 2013;**43**(12):3138-3146
- [60] Larange A, Antonios D, Pallardy M, Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. *Journal of Leukocyte Biology*. 2009;**85**(4):673-683
- [61] Hawkes JE, Gudjonsson JE, Ward NL. The snowballing literature on imiquimod-induced skin inflammation in mice: A critical appraisal. *Journal of Investigative Dermatology*. 2017;**137**(3):546-549
- [62] Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod). *Journal of the American Academy of Dermatology*. 1998;**38**(2):230-239
- [63] van Seters M, van Beurden M, ten Kate FJW, Beckmann I, Ewing PC, Eijkemans MJC, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. *New England Journal of Medicine*. 2008;**358**(14):1465-1473
- [64] Dowling JK, Mansell A. Toll-like receptors: The swiss army knife of

- p>immunity and vaccine development. Clinical and Experimental Immunology. 2016;
- 5**
- (5):e85
- [65] U.S. National Library of Medicine. Clinical trials, Toll-Like Receptor 7. 2019. Available from: <https://clinicaltrials.gov/ct2/results?cond=&term=TLR7&cntry=&state=&city=&dist=>
- [66] Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet. 2003;**361**(9358):690-694
- [67] Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatologic Therapy. 2008;**21**(1):32-41
- [68] Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nature Clinical Practice Neurology. 2008;**4**:329
- [69] Potenzieri C, Udem BJ. Basic mechanisms of itch. Clinical and Experimental Allergy. 2012;**42**(1):8-19
- [70] Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Molecular Pain. 2008;**4**
- [71] Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. The Journal of Neuroscience. 1997;**17**(20):8003-8008
- [72] Yarbrough KB, Neuhaus KJ, Simpson EL. The effects of treatment on itch in atopic dermatitis. Dermatologic Therapy. 2013;**26**(2):110-119
- [73] D'Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. International Journal of Molecular Sciences. 2013;**14**(6):12222-12248
- [74] Sayre RM, Desrochers DL, Wilson CJ, Marlowe E. Skin type, minimal erythema dose (MED), and sunlight acclimatization. Journal of the American Academy of Dermatology. 1981;**5**(4):439-443
- [75] Oertel BG, Lotsch J. Clinical pharmacology of analgesics assessed with human experimental pain models: Bridging basic and clinical research. British Journal of Pharmacology. 2013;**168**(3):534-553
- [76] Olofsen E, Romberg R, Bijl H, Mooren R, Engbers F, Kest B, et al. Alfentanil and placebo analgesia: No sex differences detected in models of experimental pain. Anesthesiology. 2005;**103**(1):130-139
- [77] Chow S, Rizzo C, Ravitskiy L, Sinha AA. The role of T cells in cutaneous autoimmune disease. Autoimmunity. 2005;**38**(4):303-317
- [78] Swaminathan A, Lucas RM, Dear K, McMichael AJ. Keyhole limpet haemocyanin—A model antigen for human immunotoxicological studies. British Journal of Clinical Pharmacology. 2014;**78**(5):1135-1142
- [79] Curtis JE, Hersh EM, Harris JE, McBride C, Freireich EJ. The human primary immune response to keyhole limpet haemocyanin: Interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clinical and Experimental Immunology. 1970;**6**(4):473-491
- [80] Weigle WO. Immunochemical properties of hemocyanin. Immunochemistry. 1964;**1**:295-302
- [81] Swanson MA, Schwartz RS. Immunosuppressive therapy. The relation between clinical response and immunologic competence. The New England Journal of Medicine. 1967;**277**(4):163-170
- [82] Perabo FG, Muller SC. Current and new strategies in immunotherapy for superficial bladder cancer. Urology. 2004;**64**(3):409-421
- [83] Grant RW, Mariani RA, Vieira VJ, Fleshner M, Smith TP, Keylock KT, et al.

Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults. *Brain, Behavior, and Immunity*. 2008;**22**(6):923-932

[84] Schuyler M, Lyons CR, Masten B, Bice D. Immunoglobulin response to intrapulmonary immunization of asthmatics. *Immunology*. 1997;**91**(2):167-175

[85] Kantele A, Hakkinen MP, Zivny J, Elson CO, Mestecky J, Kantele JM. Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines. *Clinical and Developmental Immunology*. 2011;**2011**:614383

[86] Boelens PG, Fonk JCM, Houdijk APJ, Scheper RJ, Haarman HJTM, Meijer S, et al. Primary immune response to keyhole limpet haemocyanin following trauma in relation to low plasma glutamine. *Clinical and Experimental Immunology*. 2004;**136**(2):356-364

[87] Boulton C, Meiser K, David OJ, Schmouder R. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: A 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study. *Journal of Clinical Pharmacology*. 2012;**52**(12):1879-1890

[88] Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. *Arthritis and Rheumatism*. 2010;**62**(1):64-74

[89] Saghari M, Ziagkos D, van Doorn MBA, Burggraaf J, Rissman R, Moerland M. Evaluation of delayed-type hypersensitivity (DTH) in healthy volunteers using innovative imaging techniques. Centre for Human Drug Research; 2019 [Unpublished]